Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B
Alimentary Pharmacology and Therapeutics, 04/04/2012Ghany MG et al.
Extended combination therapy with lamivudine and adefovir is associated with a high rate of long–term virological and biochemical response. Adefovir monotherapy appears to be less effective mainly because of poor initial response and the ultimate development of antiviral resistance.
Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks.
Study endpoints were :
Maintained virological (HBV DNA <500 copies/mL), biochemical and histological response
Loss of HBeAg
Loss of HBsAg.
A total of 41 patients were enrolled, including 31 HBeAg -positive and 31 treatment-naive subjects.
30 patients remained on assigned therapy at 192 weeks.
The percentage of patients achieving a combined maintained response was higher in the combination than the monotherapy arm, both at week 48 (59% vs. 26%, P = 0.06) and 192 (68% vs. 31%, P = 0.03).
At week 192, 76% of the combination vs. 36% of the monotherapy group had loss of HBeAg (P = 0.03).
One patient receiving adefovir cleared HBsAg.
Adefovir resistance developed in 6 of 19 (32%) monotherapy but none of 22 combination treated patients (P = 0.03).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.